样式: 排序: IF: - GO 导出 标记为已读
-
Anti-obesity medications: current and futureAn overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-03-12 Subir Ray, Nitin Kapoor, Neeta Deshpande, Sanjay Chatterjee, Janardanan Kumar, Om Tantia, Ghanshyam Goyal, Jagat Jyoti Mukherjee, Awadhesh Kumar Singh
With newer anti-obesity medications (AOMs) being introduced at a rapid pace, it is prudent to make a concise and updated clinical practice document that may help busy clinicians in daily clinical p...
-
Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn’s disease and ulcerative colitis Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-03-05 Geert D’Haens, Maria Rosario, Daniel Polhamus, Nathanael L. Dirks, Chunlin Chen, Krisztina Kisfalvi, Christian Agboton, Séverine Vermeire, Brian G. Feagan, William J. Sandborn
This posthoc analysis of the GEMINI and VISIBLE studies in ulcerative colitis (UC) and Crohn's Disease (CD) assessed exposure−efficacy of vedolizumab intravenous (IV) and subcutaneous (SC).A previo...
-
Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-27 Belén Toledo, Chiara Deiana, Fabio Scianò, Giovanni Brandi, Juan Antonio Marchal, Macarena Perán, Elisa Giovannetti
Treatment resistance poses a significant obstacle in oncology, especially in biliary tract cancer (BTC) and pancreatic cancer (PC). Current therapeutic options include chemotherapy, targeted therap...
-
Antiretroviral therapy response: exploring the potential influence of SARS-CoV-2 Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-23 Ahmad Z. Al Meslamani
Published in Expert Review of Clinical Pharmacology (Just accepted, 2024)
-
Therapeutic drug monitoring of antifungal therapies: do we really need it and what are the best practices? Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-21 Johannes Boyer, Martin Hoenigl, Lisa Kriegl
Despite advancements, invasive fungal infections (IFI) still carry high mortality rates, often exceeding 30%. The challenges in diagnosis, coupled with limited effective antifungal options, make ma...
-
The effect of epilepsy and antiseizure medications on cardiac autonomic functions in children with epilepsy Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-13 Sherifa Ahmed Hamed, Ali Farag El Hadad, Mohammed Aboalwafa Aldawy
Autonomic manifestations have been frequently studied in adults with epilepsy. Here, we evaluated cardiac autonomic (ANS) functions in children with epilepsy in the interictal period and determined...
-
Centering the patient in decisions about opioid tapering Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-13 J.J Fenton
Published in Expert Review of Clinical Pharmacology (Ahead of Print, 2024)
-
Integrating clinical pharmacology and artificial intelligence: potential benefits, challenges, and role of clinical pharmacologists Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-10 Harmanjit Singh, Dwividendra Kumar Nim, Aaronbir Singh Randhawa, Saher Ahluwalia
The integration of artificial intelligence (AI) into clinical pharmacology could be a potential approach for accelerating drug discovery and development, improving patient care, and streamlining me...
-
Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-10 Nicole F. Maranchick, Awewura Kwara, Charles A. Peloquin
Tuberculosis(TB) is a leading infectious diseases cause of mortality worldwide,especially for people living with human immunodeficiency virus(PLWH). Treating TB in PLWH can be challenging due to nu...
-
Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting? Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-12 Anna Sofie Buhl Rasmussen, Christen Lykkegaard Andersen, Allan Weimann, Tianwu Yang, Camille Tron, Virginie Gandemer, Kim Dalhoff, Cecilie Utke Rank, Kjeld Schmiegelow
Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and replaced hem...
-
The future of pharmacology education: The Veterinary Educators in Pharmacology Special Interest Group (VEPSIG) Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-07 Martin Hawes, Arno Werners
Published in Expert Review of Clinical Pharmacology (Vol. 17, No. 3, 2024)
-
Pharmacogenomics – a minor rather than major force in clinical medicine Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-06 Thomas M. Polasek
Pharmacogenomics (PGx) is touted as essential for the future of precision medicine. But the opportunity cost of PGx from the prescribers’ perspective is rarely considered. The aim of this article i...
-
Pharmacokinetic correlates of clinical response in a naturalistic sample of escitalopram-treated patients Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-05 Nicholas Kasperk, Ekkehard Haen, Christoph Hiemke, Thomas Frodl, Georgios Schoretsanitis, Michael Paulzen, Nazar Kuzo
We assessed pharmacokinetic correlates of treatment response to escitalopram using a large therapeutic drug monitoring database.A large naturalistic sample of patients receiving escitalopram was an...
-
The effect of different levothyroxine administration regimens on thyroid hormone levels: a systematic review, pairwise, and network meta-analysis Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-05 Bianca Vendruscolo Bianchini, Patricia Romualdo de Jesus, Renato Gorga Bandeira de Mello, Patricia Klarmann Ziegelmann, Kristian Bellevue Filion, Tatiane da Silva Dal Pizzol
This systematic review aimed to compare the effect of alternative levothyroxine administration regimens on thyroid hormone levels and patient-reported outcomes (PROs) among adults with hypothyroidi...
-
Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-02-01 Levin Thomas, Arun Prasath Raju, S. Chaithra, Shrivathsa Kulavalli, Muralidhar Varma, Chidananda Sanju SV, Mithu Baneerjee, Kavitha Saravu, Surulivelrajan Mallayasamy, Mahadev Rao
Single nucleotide polymorphisms (SNPs) in the N-acetyltransferase 2 (NAT2) gene as well as several other clinical factors can contribute to the elevation of liver function test values in tuberculos...
-
Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-31 Min Xiao, Li Li, Weiwei Zhu, Fengbo Wu, Bin Wu
Concerns regarding statin-related neurocognitive disorders have emerged in recent years. However, previous studies have reported inconsistent results. We evaluated the association between statins a...
-
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-31 Aayushi Sood, Purnoor Kaur, Omar Syed, Akshit Sood, Wilbert S Aronow, Benjamin Borokhovsky, Vishal Bhatia, Rahul Gupta
Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifi...
-
Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022 Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-29 Yikuan Du, Jinfeng Zhu, Zhuoming Guo, Zhenjie Wang, Yuni Wang, Mianda Hu, Lingzhi Zhang, Yurong Yang, Jinjin Wang, Yixing Huang, Peiying Huang, Mianhai Chen, Bo Chen, Chun Yang
Metformin has the potential for treating numerous diseases, but there are still many unrecognized and unreported adverse events (AEs).We selected data from the United States FDA Adverse Event Repor...
-
Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account? Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-29 Ramón C Hermida, Michael H Smolensky, Artemio Mojón, José R Fernández
Clinical hypertension trials typically rely on homeostatic principles, including single time-of-day office blood pressure (BP) measurements (OBPM), rather than circadian chronopharmacological princ...
-
Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β2-agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-29 Vincent Yi-Fong Su, Ting-Lin Ding, Yuh-Lih Chang, Yueh-Ching Chou, Hsuen-En Hwang, Chian-Ying Chou, Chia-Chen Hsu
This study aimed to evaluate the effectiveness and safety of fixed-dose combination (FDC) inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in bronchiectasis.A retrospective cohort study a...
-
An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-29 Christopher R. McCurdy, Abhisheak Sharma, Kirsten E. Smith, Charles A. Veltri, Stephanie T. Weiss, Charles M. White, Oliver Grundmann
Kratom (Mitragyna speciosa) has generated substantial clinical and scientific interest as a complex natural product. Its predominant alkaloid mitragynine and several stereoisomers have been studied...
-
Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-29 David S Umbaugh, Hartmut Jaeschke
Acetaminophen (APAP) overdose is the leading cause of drug-induced liver injury and can cause a rapid progression to acute liver failure (ALF). Therefore, the identification of prognostic biomarker...
-
Artificial intelligence-based model for dose prediction of sertraline in adolescents: a real-world study Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-29 Ran Fu, Ze Yu, Chunhua Zhou, Jinyuan Zhang, Fei Gao, Donghan Wang, Xin Hao, Xiaolu Pang, Jing Yu
Variability exists in sertraline pharmacokinetic parameters in individuals, especially obvious in adolescents. We aimed to establish an individualized dosing model of sertraline for adolescents wit...
-
The future of pharmacology education: a global outlook Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-29 Clare Guilding, Roisin Kelly-Laubscher, Paul White
Published in Expert Review of Clinical Pharmacology (Vol. 17, No. 2, 2024)
-
Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-29 Lucas F. Borkel, Jaime Rojas-Hernández, Luis Alberto Henríquez-Hernández, Ángelo Santana Del Pino, Domingo J. Quintana-Hernández
In psychedelic therapy, the importance of set and setting is a fundamental but under-researched assumption. The aim of this study is to correlate variables of set (psychedelic use motivation) and s...
-
Challenges, unmet needs and future directions – a critical evaluation of the clinical trial landscape in schizophrenia research Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Elias Wagner, Jurjen J. Luykx, Wolfgang Strube, Alkomiet Hasan
Developing novel antipsychotic mechanisms of action and repurposing established compounds for the treatment of schizophrenia is of utmost importance to improve relevant symptom domains and to impro...
-
Population pharmacokinetics of antibacterial agents in the older population: a literature review Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Hui-Xin Liu, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Wei Zhao, Yi Zheng
Older individuals face an elevated risk of developing bacterial infections. The optimal use of antibacterial agents in this population is challenging because of age-related physiological alteration...
-
Insights into the population pharmacokinetics and pharmacodynamics of quetiapine: a systematic review Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Lu Han, Jia-Qin Gu, Jue-Hui Mao, Xiao-Qin Liu, Zheng Jiao
Quetiapine exhibits notable pharmacokinetic and pharmacodynamic (PK/PD) variability, the origins of which are poorly understood. This systematic review summarizes published population PK/PD studies...
-
Artificial intelligence and machine learning in clinical pharmacological research Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Benjamin Mayer, Dario Kringel, Jörn Lötsch
Clinical pharmacology research has always involved computational analysis. With the abundance of drug-related data available, the integration of artificial intelligence (AI) and machine learning (M...
-
Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 KaiLi Mao, Jiang Li, XinLiang Zhu, HuaYu Sun, SongYang Zhong, WeiLi Mao
This study aimed to explore a comprehensive empirical investigation and assess SCARs related to valaciclovir or acyclovir based on FAERS database from FDA, thus providing a theoretical foundation f...
-
Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Irene García-García, Enrique Seco-Meseguer, Alberto M Borobia, Antonio J Carcas-Sansuán
The implementation of pharmacogenetic analysis within clinical trials faces methodological, ethical, and regulatory challenges, as well as tackling the difficulty in obtaining actionable informatio...
-
The outcomes of considering goals of care in medication reviews for older adults: a systematic review Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Nashwa Masnoon, Cristen George, Sarita Lo, Edwin Tan, Aagam Bordia, Sarah Hilmer
This is a systematic review of prescribing, clinical, patient-reported, and health utilization outcomes of goal-directed medication reviews in older adults.A systematic review was conducted using M...
-
Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Anum Saqib Zaidi, Gregory M Peterson, Colin M Curtain, Mohammed S Salahudeen
This study aimed to determine the clinical impact associated with adverse drug reactions (ADRs) in patients with dementia.This case-control, propensity score-matched study utilized administrative d...
-
Type of proteinuria might be essential for RAAS-I treatment in children with CAKUT Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Alessia Marcellino, Riccardo Lubrano
Published in Expert Review of Clinical Pharmacology (Vol. 17, No. 1, 2024)
-
Response to letter to the editor: therapeutic importance of proteinuria classification in children with congenital anomalies of the kidney and urinary tract Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Giulio Rivetti, Pietro Gizzone, Anna Di Sessa, Stefano Guarino, Emanuele Miraglia Del Giudice, Pierluigi Marzuillo
Published in Expert Review of Clinical Pharmacology (Vol. 17, No. 1, 2024)
-
Efficacy of pharmacological agents for the management of treatment-resistant schizophrenia: a network meta-analysis Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-26 Archana Mishra, Rituparna Maiti, Biswa Ranjan Mishra, Anand Srinivasan
The present network meta-analysis (NMA) was conducted to compare and generate evidence for the most efficacious treatment among available pharmacological interventions for treatment-resistant schiz...
-
Next-generation sequencing in pharmacogenomics – fit for clinical decision support? Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-23 Yitian Zhou, Volker M. Lauschke
The technological advances of sequencing methods during the past 20 years have fuelled the generation of large amounts of sequencing data that comprise common variations, as well as millions of rar...
-
A preliminary study on plasma concentration, short-term efficacy, and safety profile of dolutegravir in Chinese people with HIV Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2024-01-22 Dongsheng Li, Ran Xiao, Qiang Fu, Xiaojing Song, Yang Han, Xiaoli Du, Taisheng Li
This study examined the plasma concentration, clinical efficacy, and safety of dolutegravir (DTG) in Chinese people with HIV (PWH).In this observational study, HIV-positive individuals on DTG-based...
-
Correction Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-14
Published in Expert Review of Clinical Pharmacology (Ahead of Print, 2023)
-
The association between ACE inhibitors and psoriasis based on the drug-targeted Mendelian randomization and real-world pharmacovigilance analyses Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-11 Qiubai Jin, Feihong Ren, Ping Song
Although a growing number of observational studies suggest that angiotensin-converting enzyme inhibitors (ACEIs) intake may be a risk factor for psoriasis, evidence is still insufficient to draw de...
-
Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Suresh D Muthukumaraswamy
There is great interest in the use of psychedelic-assisted therapies to treat a range of mental health conditions and initial randomized controlled trials (RCTs) have generated positive results. Ho...
-
STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Siobhán McGettigan, Denis Curtin, Denis O’Mahony
STOPP/START criteria for potentially inappropriate medications (PIMs, STOPP) and potential prescribing omissions (PPOs, START) have gained considerable interest and traction since they were first p...
-
Novel insights into molecular and cellular aspects of delayed drug hypersensitivity reactions Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Abdelbaset A Elzagallaai, Michael J Rieder
Delayed drug hypersensitivity reactions (DDHRs) represent a major health problem. They are unpredictable and can cause life-long disability or even death. The pathophysiology of DDHRs is complicate...
-
Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 John T. Lear, Linda M. Morris, Dylan B. Ness, Lionel D. Lewis
Sonidegib and vismodegib are currently the only US Food and Drug Administration and European Medicines Agency-approved small-molecule Hedgehog pathway inhibitors (HHIs)for treating adults with adva...
-
Advances in the pharmacological and regulatory management of multidrug resistant Helicobacter pylori Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Theodore Rokkas, Konstantinos Ekmektzoglou
Antibiotic resistance of Helicobacter pylori (H. pylori) hampers the success of eradication and in recent years multidrug resistance (MDR) shows an increase worldwide.This review covers current asp...
-
An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Vincenzo Picone, Ylenia Vallone, Cataldo Patruno, Maddelena Napolitano
A comprehensive review of the English-language medical literature was performed searching for ongoing and closed clinical trials concerning new and emerging monoclonal antibody therapies for modera...
-
Determinants of adherence to treatment in patients with ophthalmic conditions Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Patricia Muñoz-Villegas, Humberto Martínez-Bautista, Oscar Olvera-Montaño
The objective of this study was to identify and determine factors associated with patients’ ophthalmic adherence in common ocular conditions from randomized clinical trials (RCT).A univariate analy...
-
The effectiveness of cerebrolysin, a multi-modal neurotrophic factor, for treatment of post-covid-19 persistent olfactory, gustatory and trigeminal chemosensory dysfunctions: a randomized clinical trial Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Sherifa Ahmed Hamed, Mohamed Azzam Abdel-Razek Ahmed
This trial aimed to monitor the outcomes of persistent post-covid-19 smell and taste disorders after cerebrolysin therapy, a NTF, and olfactory and gustatory trainings.This was a prospective random...
-
Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Sebastiaan C. Goulooze, Peter W. Vis, Elke H.J. Krekels, Catherijne A.J. Knibbe
Pharmacokinetic (PK)-Pharmacodynamic (PD) and exposure-response (E-R) modeling are critical parts of pediatric drug development. By integrating available knowledge and supportive data to support th...
-
JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-12-09 Kabir Sardana, Aishwarya Muddebihal, Ananta Khurana
Vitiligo is an autoimmune disorder which presents as depigmented macules due to selective loss of melanocytes. Heightened expression of Janus Kinase Signal transducers and activators of transcripti...
-
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 Milo Gatti, Federico Pea
The growing spread of infections caused by multidrug-resistant pathogens makes the need of tailoring antimicrobial therapies by means of a ‘patient-centered’ approach fundamental. In this scenario,...
-
Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician’s perspective Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 Luke J Ney, Wole Akosile, Chris Davey, Louise Pitcher, Kim L Felmingham, Leah M Mayo, Matthew N Hill, Esben Strodl
Preclinical and experimental research have provided promising evidence that medicinal cannabis may be efficacious in the treatment of posttraumatic stress disorder (PTSD). However, implementation o...
-
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the Omicron era Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 Fatima Faraz, Mohammad Ebad Ur Rehman, Abia Shahid, Muhammad Saqib Ghafoor, Huzaifa Ahmad Cheema
Published in Expert Review of Clinical Pharmacology (Vol. 16, No. 11, 2023)
-
The new evidence on cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: one step closer to their use in this setting? Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 Djordje S. Popovic, Theocharis Koufakis, Dimitrios Patoulias, Nikolaos Papanas
Chronic kidney disease (CKD) affects 30–40% of persons with type 1 diabetes mellitus (T1DM), markedly increasing the risk of kidney failure and cardiovascular events. The excessive mortality observ...
-
Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 Melisande L Addison, Priyanga Ranasinghe, David J Webb
Hypertension is the main global risk factor for cardiovascular disease. Despite this, less than half of treated hypertensive patients are controlled. One reason for this is nonadherence, a major un...
-
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized? Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 André J Scheen
Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in c...
-
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 Chara Tsiampali, Paraskevi Papaioannidou, Antonis Goulas, Stergios A. Polyzos
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease, associated with obesity, type 2 diabetes mellitus and dyslipidemia, which can lead to liver cirrhosis and hepatocellular carc...
-
Clinical pharmacology of β-3 adrenergic receptor agonists for cardiovascular diseases Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 Jean-Luc Balligand, Lauriane Y. M. Michel
Few agonists of the third isotype of beta-adrenergic receptors, the β3-adrenoreceptor, are currently used clinically, and new agonists are under development for the treatment of overactive bladder ...
-
A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 Jie Wu, Angela TH Kwan, Taeho Greg Rhee, Roger Ho, Giacomo d’Andrea, Giovanni Martinotti, Kayla M Teopiz, Felicia Ceban, Roger S McIntyre
The challenges posed by treatment-resistant schizophrenia and depressive symptoms have led to ongoing difficulties despite the availability of antipsychotics and antidepressants. This review addres...
-
Stimulant and hallucinogenic novel psychoactive substances; an update Expert Rev. Clin. Pharmacol. (IF 4.4) Pub Date : 2023-11-22 F Schifano, A Vento, N Scherbaum, A Guirguis
The renewed interest in considering a range of stimulants, psychedelics and dissociatives as therapeutics emphasizes the need to draft an updated overview of these drugs’ clinical and pharmacologic...